title: Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative.
abstract: Recently, the euglycemic hyperinsulinemic clamp technique was shown to give excellent image quality during metabolic steady-state conditions. Acipimox is a new potent nicotinic acid derivative that rapidly reduces serum free fatty acid (FFA) levels by inhibiting lipolysis in peripheral tissue.
  
  
  METHODS
  To compare the effects of acipimox administration and insulin clamp on [18F]fluorodeoxyglucose ([18F]FDG) uptake and myocardial glucose utilization, five nondiabetic and seven type II diabetic patients who had had previous myocardial infarctions were studied twice: once during a clamp study and once after the administration of acipimox (2 x 250 mg orally). All patients also underwent resting SPECT perfusion imaging prior to PET scans.
  
  
  RESULTS
  The patients tolerated acipimox well. Although fasting plasma glucose levels were higher in diabetic patients (9.2 +/- 3.4 versus 5.5 +/- 0.3 mM, p = 0.03), they were decreased both during clamping and after acipimox; during imaging, no significant differences between the groups and approaches were detected. By visual analysis, the image quality and myocardial [18F]FDG uptake patterns were similar during clamping and after acipimox. Compared with the relative [18F]FDG uptake values obtained during clamping, acipimox yielded similar results in normal, mismatch and scar segments (r = 0.88, p = 0.0001). Similar rMGU values were also obtained during both approaches.
  
  
  CONCLUSIONS
  Thus, PET imaging with [18F]FDG after the administration of acipimox is a simple and feasible method for clinical viability studies both in nondiabetic and diabetic patients. It results in excellent image quality and gives rMGU levels similar to the insulin clamp technique.
authors.affiliation: Turku Cyclotron-PET Center, Finland.
authors.forename: M J
authors.initials: MJ
authors.lastname: Knuuti
authors.forename: H
authors.initials: H
authors.lastname: Yki-Järvinen
authors.forename: L M
authors.initials: LM
authors.lastname: Voipio-Pulkki
authors.forename: M
authors.initials: M
authors.lastname: Mäki
authors.forename: U
authors.initials: U
authors.lastname: Ruotsalainen
authors.forename: R
authors.initials: R
authors.lastname: Härkönen
authors.forename: M
authors.initials: M
authors.lastname: Teräs
authors.forename: M
authors.initials: M
authors.lastname: Haaparanta
authors.forename: J
authors.initials: J
authors.lastname: Bergman
authors.forename: J
authors.initials: J
authors.lastname: Hartiala
authors.forename: U
authors.initials: U
authors.lastname: Wegelius
authors.forename: P
authors.initials: P
authors.lastname: Nuutila
mesh_terms: D000328:Adult; D000368:Aged; D017023:Coronary Angiography; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000000981:diagnostic imaging; D004452:Echocardiography; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D015309:Glucose Clamp Technique; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging; D009206:Myocardium / Q000378:metabolism; D009539:Nicotinic Acids / Q000494:pharmacology*; D011719:Pyrazines / Q000494:pharmacology*; D015635:Radionuclide Ventriculography; D014055:Tomography, Emission-Computed
chemical_list: D009539:Nicotinic Acids; D011719:Pyrazines; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose; D005947:Glucose; C027696:acipimox